Mycophenolate mofetil - Is it worth the cost? The in-favor opinion

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Since its introduction, mycophenolate mofetil (MMF) has rapidly gained acceptance among renal transplant physicians. Three large multicenter studies have shown that MMF decreased the incidence of acute rejection episodes by 50%. While clinical data supporting the long-term benefits of MMF are not available, there is some experimental evidence which demonstrates that MMF may play a role in the prevention of chronic allograft rejection. Furthermore, MMF is a potent immunosuppressive agent, which could result in a reduction of the dose of cyclosporin A (CsA) required and subsequently reduce its associated toxicity. Despite the fact that MMF is six to seven times more expenSiVe than azathioprine (AZA), its introduction into maintenance immuno- suppressive protocols may not increase renal transplant charges during the first year after renal transplant as its cost can be offset by the reduced number of acute rejection episodes (ARE). The long-term societal impact of MMF will need to be evaluated as the data related to graft and patient survival, as well as chronic rejection, become available.

Original languageEnglish (US)
Pages (from-to)79-82
Number of pages4
JournalPediatric Transplantation
Volume3
Issue number1
DOIs
StatePublished - Feb 1999

Fingerprint

Mycophenolic Acid
Costs and Cost Analysis
Transplants
Kidney
Azathioprine
Graft Survival
Immunosuppressive Agents
Cyclosporine
Multicenter Studies
Allografts
Maintenance
Physicians
Incidence

Keywords

  • Economics
  • Mycophenolate mofetil 1 pediatrics
  • Renal transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Mycophenolate mofetil - Is it worth the cost? The in-favor opinion. / Seikaly, M. G.

In: Pediatric Transplantation, Vol. 3, No. 1, 02.1999, p. 79-82.

Research output: Contribution to journalArticle

@article{eec7aa1645c948269d682fe924a460e5,
title = "Mycophenolate mofetil - Is it worth the cost? The in-favor opinion",
abstract = "Since its introduction, mycophenolate mofetil (MMF) has rapidly gained acceptance among renal transplant physicians. Three large multicenter studies have shown that MMF decreased the incidence of acute rejection episodes by 50{\%}. While clinical data supporting the long-term benefits of MMF are not available, there is some experimental evidence which demonstrates that MMF may play a role in the prevention of chronic allograft rejection. Furthermore, MMF is a potent immunosuppressive agent, which could result in a reduction of the dose of cyclosporin A (CsA) required and subsequently reduce its associated toxicity. Despite the fact that MMF is six to seven times more expenSiVe than azathioprine (AZA), its introduction into maintenance immuno- suppressive protocols may not increase renal transplant charges during the first year after renal transplant as its cost can be offset by the reduced number of acute rejection episodes (ARE). The long-term societal impact of MMF will need to be evaluated as the data related to graft and patient survival, as well as chronic rejection, become available.",
keywords = "Economics, Mycophenolate mofetil 1 pediatrics, Renal transplantation",
author = "Seikaly, {M. G.}",
year = "1999",
month = "2",
doi = "10.1034/j.1399-3046.1999.00015.x",
language = "English (US)",
volume = "3",
pages = "79--82",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Mycophenolate mofetil - Is it worth the cost? The in-favor opinion

AU - Seikaly, M. G.

PY - 1999/2

Y1 - 1999/2

N2 - Since its introduction, mycophenolate mofetil (MMF) has rapidly gained acceptance among renal transplant physicians. Three large multicenter studies have shown that MMF decreased the incidence of acute rejection episodes by 50%. While clinical data supporting the long-term benefits of MMF are not available, there is some experimental evidence which demonstrates that MMF may play a role in the prevention of chronic allograft rejection. Furthermore, MMF is a potent immunosuppressive agent, which could result in a reduction of the dose of cyclosporin A (CsA) required and subsequently reduce its associated toxicity. Despite the fact that MMF is six to seven times more expenSiVe than azathioprine (AZA), its introduction into maintenance immuno- suppressive protocols may not increase renal transplant charges during the first year after renal transplant as its cost can be offset by the reduced number of acute rejection episodes (ARE). The long-term societal impact of MMF will need to be evaluated as the data related to graft and patient survival, as well as chronic rejection, become available.

AB - Since its introduction, mycophenolate mofetil (MMF) has rapidly gained acceptance among renal transplant physicians. Three large multicenter studies have shown that MMF decreased the incidence of acute rejection episodes by 50%. While clinical data supporting the long-term benefits of MMF are not available, there is some experimental evidence which demonstrates that MMF may play a role in the prevention of chronic allograft rejection. Furthermore, MMF is a potent immunosuppressive agent, which could result in a reduction of the dose of cyclosporin A (CsA) required and subsequently reduce its associated toxicity. Despite the fact that MMF is six to seven times more expenSiVe than azathioprine (AZA), its introduction into maintenance immuno- suppressive protocols may not increase renal transplant charges during the first year after renal transplant as its cost can be offset by the reduced number of acute rejection episodes (ARE). The long-term societal impact of MMF will need to be evaluated as the data related to graft and patient survival, as well as chronic rejection, become available.

KW - Economics

KW - Mycophenolate mofetil 1 pediatrics

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=0032938954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032938954&partnerID=8YFLogxK

U2 - 10.1034/j.1399-3046.1999.00015.x

DO - 10.1034/j.1399-3046.1999.00015.x

M3 - Article

VL - 3

SP - 79

EP - 82

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 1

ER -